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SUMMARY
Organoid technology provides the possibility of
culturing patient-derived colon tissue and colorectal
cancers (CRCs) while maintaining all functional
and phenotypic characteristics. Labeling stem cells,
especially in normal and benign tumor organoids of
human colon, is challenging and therefore limits
maximal exploitation of organoid libraries for human
stem cell research. Here, we developed STAR (stem
cell Ascl2 reporter), a minimal enhancer/promoter
element that reports transcriptional activity of
ASCL2, a master regulator of LGR5+ intestinal stem
cells. Using lentiviral infection, STAR drives specific
expression in stem cells of normal organoids and in
multiple engineered and patient-derived CRC orga-
noids of different genetic makeup. STAR reveals
that differentiation hierarchies and the potential for
cell fate plasticity are present at all stages of human
CRC development. Organoid technology, in combi-
nation with the user-friendly nature of STAR, will
facilitate basic research into human adult stem cell
biology.
INTRODUCTION
The cancer stem cell model was postulated after initial transplan-
tation experiments demonstrated that only small subpopulations
of tumor cells, as few as 100, turned out to be tumorigenic while
tens of thousands of cancer cells with alternative phenotypes did
not (Al-Hajj et al., 2003; Bonnet and Dick, 1997; Lapidot et al.,
1994). For colorectal cancer (CRC), the concept gained impact
by the detection of stem cell-like cancer cells that shared func-
tional (Kreso et al., 2013; O’Brien et al., 2007; Ricci-Vitiani
et al., 2007) as well as molecular properties with normal stem
cells, like co-expression of stem cell marker genes Lgr5 and
Ascl2 (Dalerba et al., 2011). Using Lgr5 as a marker gene, the
presence of cancer stem cells in colon cancer is now well estab-
lished, revealing self-renewal and differentiation capacity for
LGR5+ tumor cells (Cortina et al., 2017; de Sousa e Melo et al.,
2017; Schepers et al., 2012; Shimokawa et al., 2017). Moreover,
re-emergence of LGR5+ cancer stem cells after their selective
targeting revealed extensive plasticity in CRCs (de Sousa e
Melo et al., 2017; Shimokawa et al., 2017), underscoring the
importance to understand the biological cues that mediate plas-
ticity and stem cell function in tumors in order to design effective
anti-cancer therapies. Although CRISPR-mediated labelings of
cancer stem cells have been achieved in CRC organoids (Cortina
et al., 2017; Shimokawa et al., 2017), it is currently still technically
challenging to mark stem cells in human colorectal organoids,
especially from normal tissue and benign tumors. As a result, it
is currently unresolved to what extent stem cell characteristics
evolve while colorectal tumors progress along the adenoma-
carcinoma sequence.
The establishment of CRC organoid biobanks, derived from
multiple patients, can capture the genetic diversity of the disease
(Fujii et al., 2016; van deWetering et al., 2015) and allow the faith-
ful evaluation of personalized drug responses to therapies in a
preclinical setting (Verissimo et al., 2016). As such, patient-
derived CRCorganoids have the potential to enable comparative
studies how diverse mutational landscapes of cancer genomes
from different patients affect the functional properties of cancer
stem cells.
To include multiple organoid lines for basic research into
human (cancer) stem cell biology, e.g., from many different
patients, disease stages, and settings, including normal and
benign colorectal tumors, we developed an ASCL2-responsive
minigene called STAR (stem cell ASCL2 reporter). STAR is
compatible with user-friendly strategies (e.g., lentiviral infec-
tions) to report stem cell activity in human colon organoids.
Using STAR, we demonstrate that stem cell-driven differen-
tiation hierarchies and cell fate plasticity are present at all
stages of the adenoma-carcinoma-sequence of human CRC
progression.
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Figure 1. ISC-Specific Reporters
(A) Transcriptional activity of indicated reporters measured by luciferase assay in HEK293T cells co-transfected with a dominant-positive mutant of b-catenin
(S33Y), ASCL2, the combination, or none. A synthetic promoter with five optimal ASCL2 binding sites is non-responsive, whereas a TOP reporter (53 TCF sites) is
predominantly sensitive to active WNT/b-catenin signaling. Combining ASCL2 and TCF sites (both 53) demonstrates a synergistic activation upon presence of
b-catenin and ASCL2. Luciferase activity was normalized to the ‘‘empty’’ pGL4.10 backbone. All transcriptional elements include TATA-box. RLU, relative
luciferase units. Triplicates of a representative experiment are shown. Data are represented as mean ± SEM.
(legend continued on next page)
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RESULTS
Intestinal Stem Cell-Specific Reporters
b-Catenin/Tcf4 transcriptional activity is key for intestinal stem
cell (ISC) fate but is also active in non-stem cells (Van der Flier
et al., 2007; van Es et al., 2005). In search of an ISC-specific re-
porter, the transcription factor Ascl2 is of particular interest
considering its role as the master regulator of ISC fate (van der
Flier et al., 2009). Ascl2 synergistically enhances the expression
level of a subset of Wnt/b-catenin target genes, thereby
imposing a stem cell-specific expression pattern on combined
Wnt/b-catenin and Ascl2 target genes such as Lgr5, Rnf43,
EphB2, and notably Ascl2 itself. As a consequence of the posi-
tive transcriptional feedback loop of Ascl2 on its own gene tran-
scription, Ascl2 converts the Wnt morphogen gradient that is
present along the crypt-villus axes into an almost binary signal
for ISC fate (Schuijers et al., 2015).
To test transcriptional activity of different ASCL2-dependent
reporters, we performed luciferase assays in human embryonic
kidney cells (HEK293T) that contain a fully functional yet inactive
Wnt signaling pathway. As expected based on previous reports
(Schuijers et al., 2015), we hardly observed any transcriptional
activity of five optimal ASCL2 binding sites in the presence of
active Wnt/b-catenin signaling, presence of ASCL2, or both
combined (Figure 1A). Indeed, in line with the proposed model
that b-catenin/TCF and ASCL2 can function as a tripartite tran-
scriptional complex (Schuijers et al., 2015), the addition of five
Wnt-responsive TCF optimal binding motifs (TOP) to ASCL2
sites provided a synergistic effect on transcriptional activity (Fig-
ure 1A). The minimal 150-bp promoter element of LGR5 (100-bp
promoter region plus first 50-bp 50-UTR) that includes an endog-
enous TATA box sequence demonstrates no transcriptional
activity by itself (Figure 1A).
To validate expression patterns of functional reporters in intes-
tinal epithelia, we generated small intestinal mouse (SIM) orga-
noids with stable integration of the reporter plasmids. Although
Wnt/b-catenin signaling is well known for its effects in stem
(arrows) and progenitor cells, the TOP reporter predominantly
shows strong Wnt activity in Paneth cells in agreement with its
reported role in specializing terminally differentiated Paneth cells
(Figure 1B) (Farin et al., 2012; van Es et al., 2005). In addition,
supplementing TOP with ASCL2 sites confirmed enhanced re-
porter expression in Lgr5+ crypt base columnar (CBC) stem cells
of SIM organoids (arrows), in line with the measurements in
cell lines (Figure 1C). However, while the signal became much
enhanced in CBC stem cells, i.e., almost equalized in relation
to Paneth cells, the lack of exclusivity for CBC cells disqualifies
this reporter for specific visualization and manipulation of Lgr5+
CBC stem cells.
To obtain stem cell specificity, we searched for enhancer
elements with exclusive responsiveness to stem cell specific
ASCL2 in publicly available chromatin immunoprecipitation
(ChIP) sequencing data of ASCL2 and TCF4 (Schuijers et al.,
2015). Intriguingly, while most binding elements revealed co-oc-
cupancy of both transcription factors, a single 700-bp enhancer
element in closest proximity, and thus annotated, to theKLHDC4
gene stood out with significant levels of ASCL2 binding without
any detectable TCF (Schuijers et al., 2015). Intriguing, the
KLHDC4 gene itself is not enriched in ISCs, nor is it known to
be important for stem cell biology. Moreover, the enhancer
element, identified in the human genome, does not seem to be
conserved among species (data not shown). Nevertheless, the
KLHDC4 enhancer in combination with the minimal LGR5 pro-
moter indeed revealed ASCL2-specific transcriptional activity
in a luciferase assay without any responsiveness to Wnt/b-cate-
nin (Figure 1D). To assess influence of the minimal LGR5 pro-
moter on transcriptional activity, we replaced this sequence
for synthetic TATA box sequences and obtained similar, albeit
lower, ASCL2-dependent effects (Figure 1D). Importantly, intro-
duction of the KLHDC4 enhancer that is driving expression of a
fluorescent marker in SIM organoids, revealed high activity at
the crypt base, flanked by non-positive CD24+ Paneth cells
(Figure 1E).
Identification of Stem Cell Activity Using an ASCL2-
Responsive Minigene
We observed that the core of the KLHDC4-related enhancer
element contained 11 near-perfect repeats of 41 bp that are
interspersed with three random base pairs. Each 41-bp repeat
contained an optimal 10-bp ASCL2-binding motif (Figure 2A).
To test whether these repeats are responsible for ASCL2-depen-
dent transcriptional activation, we repeated the luciferase assay
in 293T cells. Moreover, to validate ASCL2 specificity, we gener-
ated a mutant repeat with directed point mutations within the
core of the ASCL2 binding motif (Figure 2A). As expected, the
41-bp repeats became transcriptionally active only in the pres-
ence of ASCL2. Moreover, its activity strongly increased upon
multiplying the number of repeats, while the mutant versions
remained inactive (Figure 2B). From now, on we refer to the
41-bp repeat as STAR.
To confirm transcriptional activity of STAR repeats in combi-
nation with endogenousASCL2 expression levels, we performed
(B) Stably integrated TOP reporter (red) reveals Wnt activity in mouse small intestinal organoids. High levels of Wnt activity are observed in WGA+ Paneth cells
(green), while only low levels are observed in CBC stem cells (arrows). DAPI (blue) marks nuclei.
(C) Stably integrated ASCL2-TOP reporter (red) reveals similar expression levels between WGA+ (green) Paneth cells (dashed lines) and intercalating CBC stem
cells (arrows) at the bottom of crypt compartments in mouse small intestinal organoids. WGA (green) stains Paneth cells (dashed lines). DAPI (blue) marks nuclei.
*Autofluorescence.
(D) Transcriptional activity of indicated reporters measured by luciferase assay in HEK293T cells in co-presence of a dominant-positive mutant of b-catenin
(S33Y), ASCL2, both, or none.KLHDC4 enhancer shows ASCL2-dependent transcriptional activity and is insensitive to activeWnt/b-catenin signaling. Like TATA
box, minimal LGR5 promoter on itself is non-responsive but facilitates transcriptional activity mediated by enhancer. Addition of TOP sites to enhancer yields
b-catenin-responsive effects, as well as synergism to co-presence of ASCL2 and b-catenin. Triplicates of a representative experiment are shown. RLU, relative
luciferase units. Data are represented as mean ± SEM.
(E) Stably integrated KLHDC4 reporter (red) reveals bright signal at crypt bottoms with the exclusion of CD24+ Paneth cells (green). Hoechst (blue) marks nuclei.
Scale bars: 50 mm.
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Figure 2. Identification of Stem Cell Activity Using an ASCL2-Responsive Minigene
(A) Representation of the KLHDC4 enhancer that contains 11 near-identical 41-bp repeats. Based on these repeats, reporters were generated consisting of
normal repeats (STAR, red box) that includes an optimal binding motif for ASCL2 (red font) driving transcription of all possible genes of interest (GOIs). In contrast,
repeats with mutations in ASCL2 binding motif (blue font) function as control elements named mSTAR (blue box).
(legend continued on next page)
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the luciferase assay in LS174T CRC cell line. These human CRC
cells show robust expression levels of multiple Wnt-dependent
ISCmarkers such as LGR5, RNF43, and ASCL2 (van deWetering
et al., 2002; Van der Flier et al., 2007). As expected, multiplying
the number of STAR repeats enhanced activity, while mutant
STAR repeats remained inactive. Strikingly, four or more (eight)
STAR repeats showed activity that surpassed the original
KLHDC4 enhancer element (Figure S1A).
For molecular validation of STAR repeat-driven transcription,
we performed a DNA pull-down with STAR repeats in LS174T
CRC cells for subsequent identification of all interacting proteins
using mass spectrometry (Figure S1B). We indeed identify
ASCL2-specific binding to the STAR repeats mediated by its
consensus binding motif (Figures 2C and S1C). Moreover, the
experiment shows that STAR DNA sequences interact with two
general heterotypic binding partners of the E protein family of
bHLH transcription factors, namely HEB (TCF12) and E2A
(TCF3). Subsequently, we performed an ASCL2 pull-down in
LS174 CRC cells to identify direct protein-protein interaction
partners of ASCL2 by mass spectrometry. In agreement with
previous reports (Johnson et al., 1992; Scott et al., 2000; van
der Flier et al., 2009), HEB and E2A were observed to be the
most common binding partners of ASCL2 (Figure 2D). Moreover,
due to the presence of ethidium bromide during the experiment,
we disrupt protein DNA-dependent interactions, suggesting that
ASCL2 binds in a protein complex with HEB and/or E2A to the
STAR repeat.
To test the STAR-mediated expression pattern in intestinal or-
ganoid cultures, we generated a STAR minigene that combines
41-bp STAR repeats with the minimal LGR5 promoter to drive
expression of a fluorescent marker. As expected, introduction
of a STAR minigene into SIM organoids resulted in restricted ac-
tivity in CBC stem cells at the base of crypt structures with the
notable exception of Lysozyme+ Paneth cells (Figure 2E). To
confirm stem cell-specific STAR activity, we determined its
expression pattern in relation to stem cell marker gene Lgr5.
We isolated SIM organoids from the Lgr5-DTR-GFP mouse in
which Lgr5+ CBC stem cells are marked with DTR-GFP (Tian
et al., 2011). We observed co-expression of STAR in DTR-
GFP+ Lgr5 stem cells as assessed by their GFP+ membranes,
as well as exclusion of STAR expression in Lysozyme+ Paneth
cells (Figure 2F). In contrast to the observed heterogeneity in
organoids, STAR activity in clonal human CRC cell lines showed
a more homogeneous expression pattern, where averaged
levels of STAR activity correlated with previous reported
ASCL2 expression levels for the different cell lines (Figure S1D)
(Van der Flier et al., 2007). Notably, upon induced differentiation
of these cancer cells using transient transfection of dnTCF4, we
noticed that the activity of STAR correlates with downregulation
of LGR5 expression on the single-cell level (Figure S1E). In sum-
mary, activity of the STAR minigene faithfully represents ISC
activity that is mediated by the stem cell-specific transcription
factor ASCL2.
STAR Minigene Reveals Stem Cell Activity in Human
Organoids of Normal Colon
Considering the unmet demand for selective labeling of stem
cells in colon organoids of human origin, we tested the expres-
sion pattern of lentiviral STAR minigenes in human colon orga-
noid lines. We first validated its expression pattern in normal
human colon organoids and noticed restricted expression in
crypt-like structures reminiscent of the expression pattern in
mouse small intestinal organoids and in agreement with the
in vivo localization of Lgr5+ stem cell activity at the crypt base
(Figure 3A). Moreover, STAR+ cells were intercalated between
STAR-negative cells (arrowheads), most likely reflecting ‘‘Paneth
cell-equivalent’’ deep crypt secretory (DCS) cells that support
stem cell function in the colon (Rothenberg et al., 2012; Sasaki
et al., 2016).
Next, we determined outgrowth potential of fluorescence-
activated cell sorting (FACS)-sorted STAR+ and STARneg cells
from normal human colon organoids that contain crypt and vil-
lus-like structures. As expected, colony formation was most
robust for colon cells with STAR-labeled stem cell activity, and
almost negligible for non-STAR cells. Moreover, we noticed
that the amount of WNT and R-spondin in the culture medium
corresponded with the overall efficiency of colony formation for
the STAR+ colon cells, but not for the non-STAR cells (Figure 3B).
Independently, when normal human colon organoids are grown
in previous reported expansion medium (Sato et al., 2011), we
(B) Transcriptional activity of indicated reporters measured by luciferase assay in HEK293T cells co-transfected with a dominant-positive mutant of b-catenin
(S33Y), ASCL2, the combination, or none. STAR repeats are responsive to ASCL2 and insensitive to activeWNT/b-catenin signaling. Moreover,mSTAR is inactive
under all conditions, underscoring ASCL2-specific transcriptional activity of STAR repeats. As a positive control, combining TCF binding sites (TOP) with minimal
ASCL2 binding sites renders responsiveness to WNT/b-catenin and provides synergistic activity with co-occupancy of b-catenin/TCF and ASCL2. All tran-
scriptional elements are supplemented with min.LGR5 promoter. RLU, relative luciferase units. Triplicates of a representative experiment are shown. Data are
represented as mean ± SEM.
(C) Pulldown of DNA oligos containing 43 STAR or 43 mSTAR repeats in CRC cell line LS174T followed by mass spectrometry to identify STAR-specific in-
teracting proteins. Scatterplot indicates significant interactors (red circles) that show specific binding to the STAR repeat. As expected, bHLH transcription factor
ASCL2, as well as its heterodimeric binding partners HEB (TCF12) and E2A (TCF3) show specific binding.
(D) Mass spectrometry-based identification of non-DNA-mediated protein-protein interaction partners of ASCL2 in LS174T CRC cells. Volcano plot indicates
specific interactors with pulled-down flag-ASCL2.
(E) Left: Immunofluorescence cross-section image of stably integrated STAR minigene reveals STAR activity (red) in mouse small intestinal organoids. Middle:
Enlargement of stem cell niche reveals specific expression in CBC stem cells (arrowheads) that directly flank post-mitotic Paneth cells stained with lysozyme
(blue). Right: 3D rendering of the same organoid, clearly indicating the restrictive expression pattern of the STAR minigene in the direct vicinity of Paneth cells.
DAPI (white) marks nuclei.
(F) Left: Immunofluorescence image of stably integrated STAR minigene in mouse small intestinal organoids derived from Lgr5-DTR-eGFP knock-in mice. Co-
expression of STAR minigene (red) with Lgr5 (green) in CBC stem cells. Right panel: Enlargement of crypt compartment. Lysozyme (blue) stains Paneth cells.
DAPI (white) marks nuclei. Scale bars: 50 mm (left) and 25 mm (right). See also Figure S1.
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Figure 3. STAR Minigene Reveals Stem Cell Activity in Human Organoids of Normal Colon
(A) Cross-section of crypt structure of normal human colon organoids with stable integration of the STARminigene. Stem cells visualized by STAR activity (second
panel in white) are confined to cells at the crypt base. In line with cellular positioning in in vivo crypt, STAR+ cells are intermingled with STARneg cells (arrowheads).
Nuclei are marked with H2B-mNeonGreen expression (third panel in white). Right panel: Overlay of STAR expression (red) and nuclei (green). *Autofluorescence.
Scale bar: 25 mm.
(B) Colony-forming efficiency of single STAR+ and STARneg cells, FACS isolated frommature organoid structures with crypt and villus-like structures. At day 5 and
10 after plating, STAR+ colon cells are most potent in organoid formation. Increasing activity of the WNT signaling pathway with WNT and R-spondin ligands
enhances organoid formation efficiency of STAR+ colon cells, but not of STARneg cells. N = 3 independent experiments. Data are represented as mean ± SEM.
(C) Gene expression profiling of STAR+ versus STARneg cells from normal human colon organoids. Shown are the changes in expression levels of genes between
STAR+ and STARneg cells.
(D) GSEA on gene expression dynamics of STAR+ versus STARneg colon cells with the previously published gene set that is specific for Lgr5+ ISCs. The strong ISC
signature in STAR+ cells confirms that the STAR minigene indeed marks stem cells in normal human colon organoids. See also Figure S2.
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Figure 4. STAR Minigene Reveals Stem Cell Activity in Engineered Tumor Organoids
(A) Tumor progression organoids (TPOs) that are representative of different stages along the adenoma-carcinoma sequence. Representative organoids of TPO
subtypes are presented at day 10 after single-cell plating. Top row shows bright field. Middle row depicts STAR expression (white). Bottom row shows merge
(legend continued on next page)
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noticed significantly improved outgrowth for the non-STAR cells,
indicative of fate plasticity within this non-stem cell population to
dedifferentiate toward stem cell state upon stem cell-favorable
culture conditions (Figure S2A).
Subsequently, we performed RNA sequencing on sorted co-
lon cells with either presence or absence of STAR-labeled
stem cell activity (Figure S2B). As expected, among themost up-
regulated genes in STAR+ colon cells is ASCL2, the master regu-
lator of stemcell fate and the inducer of STAR activity (Figure 3C).
In addition, known stem cell genes such as ZNRF3, EPHB3, and
LRIG1 were upregulated. In contrast, colon cells without stem
cell activity express differentiation markers such as BMP3,
ALPI, TFFs, and Mucins. To assess the gene expression profile
of STAR+ cancer stem cells in an unbiased manner, we per-
formed a gene set enrichment analysis (GSEA) comparing our
data with available gene signatures of ISCs (Mun˜oz et al.,
2012). The gene expression signature of STAR+ colon cells re-
sembles Lgr5+ ISCs to a large extent (Figure 3D), implying that
the STAR-labeled cells in normal human colon organoids are
indeed LGR5+ colon stem cells.
STARMinigeneReveals StemCell Activity in Engineered
Tumor Organoids
Tumor progression organoids (TPOs) are normal colon organo-
ids in which various combinations of cancer mutations were
introduced using CRISPR/Cas9, thereby recapitulating various
stages of CRC development along the adenoma-carcinoma
sequence (Drost et al., 2015). STAR activity across the panel of
TPOs with identical genetic background enables us to study
the functional properties of stem cells while colon tumors evolve
from benign lesions to invasive cancers. All TPO lines of the ad-
enoma-carcinoma sequence revealed presence of STAR activity
in a heterogeneous expression pattern (Figure 4A), in line with
previous reports that signaling pathways, including Wnt, still
display heterogeneous activity patterns in malignant tissue (Pra-
setyanti et al., 2013). Especially the Quadruple mutant TPO line,
i.e., APC, KRAS, TP53, and SMAD4, showed pronounced STAR
activity confined to crypt-like budding structures, suggesting
intense stem cell activity in TPO subtypes that is associated
with invasive behavior (Drost et al., 2015; Fumagalli et al., 2017).
Since the relative level of STAR activity in TPO subtypes might
be influenced by culture media with customized growth factor
supplements, we xenotransplanted the TPO lines into the cecum
of mice in order to test whether the proportion of cancer cells
with STAR+ stem cell activity differs between different stages
of tumor development (Figure 4B). Previous studies (Drost
et al., 2015; Fumagalli et al., 2017) indicated successful engraft-
ment of the Triple, i.e.,APC,KRAS, and TP53, and theQuadruple
mutant lines. In agreement with those studies, our Triple mutant
TPO remains a tumor in situ while the Quadruple mutant TPO
showed irregular structured epithelium, a feature of invasive car-
cinomas (Figure S3A). In agreement with recent observations of
LGR5 expression patterns in human tumors (Shimokawa et al.,
2017), STAR+ cancer cells were detected at the outer regions
of the tumors. This was particularly pronounced in the Quadruple
mutant TPO (Figure 4B). Subsequent quantification of STAR+
cancer cells by FACS analysis revealed that the invasive
Quadruple mutant tumor had an increased proportion of cancer
stem cells as compared with the Triple mutant tumor (Figure 4C).
Next, we performed mRNA expression profiling of the STAR+
cells that were derived from the Quadruple mutant tumor in the
mouse versus STAR+ cells from cultured Quadruple mutant
TPO line. Reassuringly, the cellular identities of STAR+ cells
from both sources are very similar in overall expression profile
(R2 of 0.94) (Figure 4D). Moreover, when specifically analyzing
previously determined ISC-enriched genes (Mun˜oz et al.,
2012), we noticed that the ISC signature in STAR+ cells is very
robust and seems largely independent of environmental condi-
tions (R2 of 0.93) (Figure 4D).
STAR+ Cancer Cells Contain Stem Cell Activity
In order to define a comprehensive gene expression signature
for STAR+ stem cells while they evolve along the adenoma-car-
cinoma sequence of CRC development, we performed RNA
sequencing on sorted STAR+ and STARneg cancer cells from
multiple human TPO subtypes (Figures S3B and S4A), including
the original normal organoids. We consistently identified 638
genes with significant differences in expression levels between
the two populations. Among the most upregulated genes in
STAR+ cancer cells is ASCL2, the master regulator of stem cell
fate and the inducer of STAR activity (Figure 5A). In addition,
known stem cell genes such as RGMB, SP5, EPHB3, and
LRIG1 were consistently upregulated. In contrast, cancer cells
without stem cell activity had consistent expression of differenti-
ation markers such as REG4, VILLIN, and KRT7. To assess the
gene expression profile of STAR+ cancer stem cells in an unbi-
ased manner, we performed a GSEA comparing our data with
available gene signatures of ISCs (Mun˜oz et al., 2012). The
gene expression signature that is common among STAR+ cells
of the different TPO subtypes resembles Lgr5+ ISCs to a large
extent (Figure 5B), implying that the STAR+ cells in human tumor
organoids represent the genuine LGR5 stem cell lineage. In
between STAR expression (red) and H2B-mNeon (green). Cellular heterogeneity within clonally grown organoids is clearly reflected by the restricted STAR
expression pattern (dashed lines). Normal human colon and APC organoids were supplemented with Rock-inhibitor Y-27632 to prevent anoikis at single-cell
stage. *Autofluorescence. Scale bars: 50 mm.
(B) Orthotopic transplantation of human TripleAPC/ KRAS/ TP53 and Quadruple mutant STAR organoids into the cecal wall of immune-deficient mice. Tumors were
analyzed approximately 8–12 weeks after transplantation. TripleAPC/ KRAS/ TP53 remains tumor in situ and contains clusters of STAR+ cells, whereas the Quadruple
mutant tumor shows an invasivemorphologywith STAR+ cells localized at the outer regions. STAR activity is depicted in red, and counterstaining with b-catenin in
white. *Autofluorescence of necrotic debris. Scale bars: 100 mm.
(C) H2B-mNeon+ tumor cells from transplanted TripleAPC/ KRAS/ TP53 and Quadruple mutant tumor organoids were FACS sorted and gated on STAR activity
(tagBFP2). Gating settings were defined using intestinal cells of the recipient mice.
(D) Scatterplot indicating the correlation between the expression profiles of STAR+ cancer cells from the Quadruple mutant tumor organoids that have been
cultured in vitro versus grown in vivo as an orthotopic transplanted tumor. Red dots represent mRNA transcripts from a previously described ISC-specific gene
signature (Mun˜oz et al., 2012). See also Figure S3.
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Figure 5. Characterization of STAR+ Cancer Stem Cells during Tumor Progression
(A) Gene expression profiling of STAR+ versus STARneg cells from various TPO subtypes. Shown are the 638 transcripts whose average over five samples
show >1.25-fold difference. Mann-Whitney U test, p value < 0.005.
(B) Top: GSEA on gene expression dynamics of STAR+ versus STARneg cancer cells with the previously published gene set that is specific for Lgr5+ ISCs. The
strong ISC signature in STAR+ cells confirms that the STAR minigene labels cancer cells with stem cell activity in human tumor organoids that is independent of
mutational landscapes. Bottom: GSEA with the specific gene list for DCS cells shows strong DCS cell signature in STARneg cells, suggesting the presence of
DCS-like-cancer cells within the non-stem cell population.
(C) Colony-forming efficiency of single STAR+ or STARneg cells scored at days 5 and 10 after plating. Normal human colon and APC-deficient cells were sup-
plemented with Rock-inhibitor Y-27632 to prevent anoikis at the single-cell stage. N = 3 independent experiments. Data are represented as mean ± SEM.
(D) Cellular differentiation and fate plasticity create cellular heterogeneity of STAR expression within developing organoids. Three categories were assigned for an
organoid phenotype: 100% positive for STAR expression (red), complete absence of STAR expression (white), or everything in between (mixed). Phenotypes
were scored at days 0, 5, and 10 after plating. N = 3 independent experiments. Data are represented as mean ± SEM. See also Figure S4.
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agreement with the concept that common cancer mutations
eliminate the dependency of niche signals rather than inducing
de novo phenotypes (Fujii et al., 2016; Fumagalli et al., 2017),
we observed that the general stem cell signature of STAR+ cells
stays similar during tumor progression along the adenoma-car-
cinoma sequence.
Normally, colon stem cells and DCS cells are both positioned
at the entire base of a crypt. Since the STAR minigene marks
stem cell activity in a heterogeneous fashion in all TPO subtypes,
we wondered whether the STARneg population of cancer cells
include cells that resemble the DCS cells of the colon. From pre-
viously performed gene expression analysis of Reg4+ DCS cells
(Sasaki et al., 2016), we generated a Reg4+ DCS cell-specific
gene signature consisting of 208 genes that are >2-fold upregu-
lated with a p value of <0.05. Although multiple cellular lineages
are likely present within the STARneg cell population, the STARneg
tumor cell population from different TPO subtypes shows resem-
blance to the expression signatures of differentiated DCS cells
(Figure 5B), indicating that at least a subset of tumor cells are
DCS-like cells.
To study evolving characteristics of STAR+ stem cells while tu-
mors progress from benign lesions to invasive carcinomas, we
studied outgrowth potential of FACS-sorted STAR+ and STARneg
cells of multiple TPO subtypes. The growth course of individual
organoids was examined over time using brightfield imaging
and fluorescent imaging of the nuclei (H2B-mNeonGreen) and
STAR-labeled stem cell activity. Independent of TPO subtype,
we observed three modes of outgrowth for STAR+ cells. First,
the developing tumor organoids remain 100% positive for
STAR activity. Alternatively, they lose STAR activity completely.
In the third scenario, STAR+ cancer cells both self-renew into
STAR+ daughter cells, but also generate STARneg progeny by
means of differentiation, yielding organoids with amixed compo-
sition of STAR+ and STARneg cells. Profiting from this ‘‘mixed’’
outgrowth scenario, we isolated STAR+ and STARneg cells
from organoids that developed in 2 weeks from the FACS-sorted
STAR+ cell population for quantitative follow-up experiments.
Importantly, this experimental strategy excludes silencing
of the minigene as a cause of absence for STAR activity
(Figure S4A).
We first set out to further define colony-forming efficiencies of
STAR+ and STARneg cells isolated from the various TPO tumor
subtypes. Normal colon and the more benign tumor organoid
lines, i.e., with single mutations in APC or KRAS, require inhibi-
tion of anoikis-mediated apoptosis in order to grow out (Fig-
ure 5C). Anoikis inhibition can be omitted for TPO tumor variants
containing two or more cancer mutations. Although the TPO line
with APC and TP53 deficiency showsmodest but significant col-
ony formation without anoikis inhibition, combining APC-defi-
ciency with oncogenic KRAS shows increased efficiency of
organoid formation. Further addition of a third (TP53) and/or
fourth (SMAD4) mutation show similar efficiencies (Figures 5C
and S4B).
Intriguingly, the colony-forming efficiencies for STARneg cells
revealed almost identical behavior as STAR+ stem cells, albeit
with slightly lower efficiencies (Figure 5C). In a parallel experi-
ment, anoikis was inhibited for all TPO subtypes (Figures S4B
and S4C), equalizing the overall colony formation efficiencies
to similar levels among all TPO tumor lines. Also in this experi-
ment, outgrowth from STAR+ and STARneg cells gave strikingly
similar results.
Next, we decided to study the outgrowth of STARneg cells in
closer detail. At day 0, FACS-sorted cells were confirmed to be
nearly purely STARneg as assessed under the confocal micro-
scope. However, when the same organoids were imaged at later
time points (day 5 and 10), an increasing number of organoids
reobtained STAR+ cells that resulted in organoids of mixed
composition (Figure 5D, bottom panels), indicative of cell fate
plasticity. In identical experiments, the STAR+ cells transformed
from a pure population (day 0) into a population of organoids
where an increasing number of organoids showed a mixed
phenotype (Figure 5D, upper panels), indicative of STAR+ stem
cells that not only self-renew but also generate STARneg
progeny. Besides mixed phenotypes, some organoids lost all
STAR+ stem cell activity, while a small but significant fraction
of organoids remained completely composed of STAR+ stem
cells (Figure 5D, top panels).
In addition to the presence of robust de-differentiation poten-
tial of progenitor cells within normal crypt compartments in mice
(Buczacki et al., 2013; Metcalfe et al., 2014; Tetteh et al., 2016;
Tian et al., 2011; van Es et al., 2012), we now reveal similar pres-
ence of de-differentiation capacity in normal human colon.
Moreover, the capacity for fate plasticity of STARneg progenitors
does not seem to be dramatically enhanced after acquisition of
common cancer mutations.
Cancer stem cells have previously been identified in CRC
samples based on their high level of Wnt signaling using WNT/
b-catenin reporters (i.e., TOP reporters) (Vermeulen et al.,
2010). As expected, most prominent WNT-responsive cells in
tumor organoids are also labeled with STAR (Figure S4D). More-
over, reflecting the binary expression pattern of ASCL2 in intes-
tinal and colon stem cells as observed in normal crypts, we
noticed amore restrictive expression pattern of STAR in compar-
ison to the wider WNT gradient in tumor organoids. Therefore, in
addition to simple labeling of stem cells, the stem cell-exclusive
expression pattern that is imposed by STAR also provides the
unique opportunity to specifically manipulate cellular processes
that occur in stem cells by overexpression of any protein-of-
interest, e.g., dominant-negative or active effectors of signaling
pathways.
STAR Minigene Labels Cancer Stem Cells in Patient-
Derived CRC Organoids
Next, we introduced STAR minigenes in three different patient-
derived CRC organoid lines from a well-characterized multi-pa-
tient organoid biobank (van deWetering et al., 2015). Each of the
three lines, i.e., P9T, P16T, and hypermutated P19bT, contain
different mutational landscapes (Figure 6A). In clonal outgrowths
of these patient-derived CRC organoids, thereby ensuring
genetic homogeneity, different levels of STAR-labeled stem
cell activity were observed (Figure 6A). Thus, heterogeneous
patterning of STAR reported stem cell activity seems to be a
common theme among organoids from healthy, early tumori-
genic (TPOs) or end-stage CRC tissue.
Next, we performed mRNA expression profiling of the STAR+
and STARneg cells. As expected, also in these patient-derived
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CRC organoids, the STAR minigene marks cancer cells with an
expression pattern that closely associates with the stem cell
signature of well-characterized Lgr5+ ISCs from mouse (Fig-
ure 6B). Subsequently, we compared the STAR-specific expres-
sion profiles of patient-derived CRC organoids with the RNA
expression data from STAR+ stem cells of the TPO subtypes.
Genes consistently upregulated in STAR+ stem cells when
compared to STARneg cancer cells include well-known stem
cell marker genes such as ASCL2, EPHB3, NOTCH1, SOX4,
and AXIN2 (Figure 6C). In contrast, among the most differential
genes upregulated in the STARneg cancer cells is REG4, the
marker gene of DCS cells, the Paneth cell equivalent cell in colon
epithelium that supports stem cell function (Figure 6C).
In addition, we addressed the functional characteristics of the
cancer cells with or without STAR+ stem cell activity. In line with
the observations with the TPO subtypes, we observed near-
identical colony-forming efficiencies for STAR+ and STARneg
cancer cells and observed, again, significant fate plasticity (Fig-
ures 6D, 6E, and S5A). The degree of plasticity varied per pa-
tient-derived tumor line, potentially reflecting the differences in
the mutational landscape.
DISCUSSION
Organoid technology is a rapidly expanding research field. Its
unique resemblance to in vivo epithelia not only draws attention
from adult stem cell biologist, but a far wider public that ranges
from tissue engineers and biophysicist for understanding self-
organizational properties of tissues to physicians that strive
to optimize disease modeling (Clevers, 2016). Considering
this widespread mode of applications, user-friendly technology
that enables straightforward monitoring and manipulation of
specific cell types is of great interest. Especially labeling stem
cells in human intestinal organoids is challenging and has so
far only been demonstrated in colon organoids of cancerous
origin using CRISPR knockin strategies that are both technically
challenging and time consuming (de Sousa e Melo et al., 2017;
Shimokawa et al., 2017).
Here, we report the STAR minigene as an alternative strategy
for ISC labeling. The STAR minigene reports transcriptional ac-
tivity of ASCL2, the master regulator of ISC fate (van der Flier
et al., 2009) and as a result generates an expression pattern
that is specific for stem cells of the gut. Importantly, due to the
small size of the enhancer/promoter element (0.5 kb), STAR
is compatible with standard transposon-based and lentiviral
infection protocols for genomic integration. Therefore, in
contrast to CRISPR-mediated strategies, STAR provides a sim-
ple and flexible strategy to fluorescently label and/or drive all
sorts of proteins-of-interest in ISCs. Illustrative for its user friend-
liness is the successful labeling of stem cells in human colon
organoids of normal origin using lentiviral infection.
In line with previous reports, we confirm that synthetic pro-
moters with a repeating number of minimal ASCL2-optimal
binding motifs do not provide transcriptional activity in an
ASCL2-dependent manner (Schuijers et al., 2015). In contrast,
multiple 41-bp STAR repeats do generate strong transcriptional
activity. It will be interesting to identify the exact molecular
mechanism how ASCL2 initiates transcriptional activity from a
STAR repeat. Most importantly, all our data indicate that STAR
activity is critically dependent on the presence of ASCL2 and
hence is specific for stem cells of the gut.
Recently, the functional relevance of LGR5+ cancer stem cells
has been reported for primary tumor growth in CRC (Cortina
et al., 2017; de Sousa e Melo et al., 2017; Shimokawa et al.,
2017).We confirm their findings of extensive plasticity in different
patients CRCs, the presence of which seems virtually indepen-
dent of the mutational landscape and that will likely impact the
potential of cancer stem cells as a therapeutic target. In addition,
using TPO subtypes representing the different stages of the ad-
enoma-carcinoma sequence in CRC, we now show that the ca-
pacity for cell fate plasticity is present during the entire process
of tumorigenesis in human colon. Moreover, in line with mouse
studies (Buczacki et al., 2013; Metcalfe et al., 2014; Tetteh
et al., 2016; Tian et al., 2011; van Es et al., 2012), we now confirm
for human colon that the capacity of cancer cells to de-differen-
tiate is independent of the acquisition of multiple cancer muta-
tions, but predominantly a feature inherited from normal cells.
In contrast, the acquisition of cancer mutations, especially the
addition of oncogenic KRAS on top of APC deficiency, does
have a significant impact on the efficiency of individual cancer
cells to form organoids. However, this is independent of stem
cell activity, but merely reflects the capacity of individual cancer
cells to survive at the single-cell stage since plating efficiency
could be rescued in normal and benign tumor organoids by inhi-
bition of anoikis.
Besides stem cell-specific expression in small intestine and
colon, expression of ASCL2 has recently been documented in
cancerous tissues of among others lung, stomach, and breast
(Wang et al., 2017). Although gene silencing has been reported
for ASCL2 in a number of individual CRCs, potentially excluding
such samples for STAR applications (Jubb et al., 2006), it will be
of great interest to verify whether ASCL2 alsomarks stem cell ac-
tivity in tumorigenic lesions of other organs, as well as in their
corresponding normal epithelia. Libraries of patient-derived
colorectal organoids have recently been generated that also
include benign tumor samples and the organoid cultures of the
Figure 6. STAR Minigene Labels Cancer Stem Cells in Patient-Derived CRC Organoids
(A) Patient-derived CRC organoids P9T, P16T, and P19bT with stable integration of the STARminigene. Top: Bright-field images. Middle: Heterogeneous pattern
of STAR activity (white). Bottom: Merge of STAR expression (red) with H2B-Neon (green). Dashed lines indicate individual STAR+ cells. Panel at the right indicates
overview of mutations in frequently mutated genes in cancer. Panel is reproduced from van de Wetering et al. (2015). Scale bars: 50 mm.
(B) GSEA on gene expression dynamics of STAR+ versus STARneg cancer cells from TPOs and patient-derived CRC organoids shows again a strong ISC-specific
gene signature in STAR+ cancer cells.
(C) Heatmap of STAR-specific gene expression dynamics (Mann-Whitney U test, p value < 0.005) in multiple patient-derived CRC organoids and TPO subtypes
reveals stem cell and differentiation markers in STAR+ and STARneg cells, respectively.
(D and E) Like Figure 5C (D) and Figure 5D (E), but now for indicated patient-derived CRC organoids. See also Figure S5.
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normal epithelia (Fujii et al., 2016; van de Wetering et al., 2015).
CRISPR/Cas9-mediated knockins have been used to label stem
cell markers in human organoids, but their feasibility is techni-
cally challenging and has so far only been shown in CRC organo-
ids of advanced stages (Cortina et al., 2017; Shimokawa et al.,
2017). The STARminigene is an alternative user-friendly strategy
to label stem cells in intestinal organoids that has the potential to
empower easy accessible stem cell research using primary
human colon tissues from multiple different patients and patho-
genic conditions.
EXPERIMENTAL PROCEDURES
For a detailed description of experimental procedures, please see Supple-
mental Experimental Procedures.
Organoid Cultures
Mouse organoids were established and maintained as described previously
(Sato et al., 2009). Patient-derived colon organoids were maintained as
described previously (van deWetering et al., 2015). The TPO series weremain-
tained as described previously (Drost et al., 2015). For maturation of normal
colon organoids that include true crypt and villus-like structures, organoids
are grown in 15% Wnt15 culture medium (CM) and 7.5% R-spondin CM
without SB202190 and nicotinamide. To confirm correct sample identity in
the laboratory, used organoid lines were regularly tested by SNP analysis.
Genomic Integration Minigene
Organoid transfection using Tol2 transposase was performed with following
reporter plasmids: Tol2 KLHDC4-min.pLGR5-tagRFPt_PGK-puro (in SIM Bl6
organoids); Tol2 8xSTAR-min.pLGR5-mNeonGreen_PGK-puro (in SIM Bl6 or-
ganoids); Tol2 8xSTAR-min.pLGR5-tagRFPt_PGK-puro (in SIM Lgr5-DTR-
GFP organoids); Tol2 5xTOP-tagRFPt_PGK-Puro (in SIM Bl6 organoids and
in human TripleAPC/ KRAS/ TP53 and Quadruple mutant STAR colon organoids);
Tol2 5XAscl2-5xTOP-tagRFPt_PGK-Puro (in SIM Bl6 organoids) (genomic
location of KLHDC4 enhancer [chr16: 87732692–87733464]).
Alternatively, we infected TPOs and patient-derived CRC organoids
P16T and P19bT with a lentiviral vector containing 4xSTAR repeats driving
TagBFP2 expression linked with an IRES sequence to a blasticidin selection
cassette (pLV-4xSTAR-min.pLGR5-TagBFP2-IRES-Blast.) and a pLV-H2B-
mNeonGreen-IRES-puro. P9T was infected with pLV-4xSTAR-min.pLGR5-
TagRFPt::PGK-Puro-P2A-H2B-mNeonGreen. To exclude silencing of the
minigenes during culture, the STAR-infected organoids were sorted by
FACSAria III (BD Biosciences) for STARhigh cells 2 weeks before each
experiment.
Microscopy, Live-Cell Imaging, and Colony-Forming Efficiency
Images were captured with a Leica SP8X microscope. For immunofluores-
cence analyses, themouse organoidswere washedwith PBS for 1 hr, permea-
bilized with PBD0.2T (48.5 mL of PBS, 1 mL of 10% Triton, 0.5 mL of DMSO,
and 0.5 g of BSA), and incubated with antibodies at 4C overnight.
For live-cell analysis, sorted STAR+ and STARneg cells were plated on a
glass-bottom 384-well plate (Corning 4581) and mounted onto a Leica SP8X
microscope. The plate was held at 37C in a microscope box and equipped
with a culture chamber for humidity and 6.4% CO2 overflow. Organoids
were imaged in XYZ(T)-mode using a water 253 objective (HCX IRAPO L; nu-
merical aperture [N.A.], 0.95) with a tunable white light laser. For higher magni-
fication and identification of STAR-positive cells, we used a water 403 objec-
tive (HC PL APO CS2; N.A., 1.1). Post-acquisition analyses of phenotypes was
performed manually using ImageJ.
For the colony-forming efficiency assays, 3,000–5,000 viable single
cells were collected via FACS and plated over five wells with a density of
50–300 cells per well of a glass-bottom 384-well plate. Using bright-field
and live-fluorescence imaging, single cells were monitored at day 0 and at
several days of culture organoid to quantify organoid formation (colony-form-
ing efficiency %).
Cell Transfection and Dual-Luciferase Assay
The generated reporters were constructed in a pGL4.10 backbone and trans-
fected with Xtremegene9 (Roche) in all cell lines, with Renilla luciferase as a
transfection control. The dual-luciferase assay system of Promega was used
to measure reporter activity. Empty pGL4.10 or pGL4.10-min.hLGR5 served
as negative controls. All luciferase activities were normalized to Renilla. Re-
porter activities were normalized to pGL4.10-min.hLGR5 promoter.
STAR Interaction Studies
Nuclear extracts were prepared from LS174T cells. DNA oligos of the 43STAR
and 43mSTAR repeats were amplified using biotinylated primers. LS174T nu-
clear extract was combined with protein incubation buffer and added to the
beads. Pull-downs were performed in duplicate. Afterward on bead digestion
was used to digest the proteins in tryptic peptides. The label-free ASCL2-flag
pull-down was performed in triplicate using 20 mL of anti-FLAG M2 affinity gel
(Sigma) per pull-down. Afterward on bead digestion was used to digest the
affinity purified proteins in tryptic peptides. Finally, the tryptic peptides were
acidified and desalted using C18 Stagetips prior to mass spec analysis. For
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of
the DNA pull-down and the label-free FLAG pull-down, the tryptic peptides
were separated by an Easy-nLC 1000 (Thermo Fisher) connected online to
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). MaxQuant
(version 1.5.1.0) was used to analyze the rawMS spectra by searching against
the Uniprot curated human proteome (downloaded December 2015).
Orthotopic Xenotransplantation of Organoids
The orthotopic transplantation of organoids was executed as previously
described (Fumagalli et al., 2017).
RNA Sequencing
RNA from the FACS-sorted organoids was extracted using the RNeasy RNA
extraction kit (QIAGEN) with DNaseI treatment. A maximum of 250 ng of
RNA per sample was used for ribosomal RNA depletion using the Ribo-Zero
Gold rRNA removal kit (Illumina). A maximum of 2 ng of cDNA per sample
was used for library preparation using the Kapa Hyper Prep Kit (KAPA Bio-
systems). Sequencing was performed using a Illumina HiSeq 2000 machine
and generated 50-bp paired-end reads.
GSEA
For GSEA, we used the ISC signature from Mun˜oz et al. as ISC gene set. To
define a REG4+ DCS gene set, we compared available RNA sequencing
data of Lgr5+ and Reg4+ DCS cells from Sasaki et al., and considered the
genes with at least a 2-fold upregulation and a p value < 0.05 (by Student’s
t test) as a REG4+ DCS-specific gene signature. Human orthologs of both
gene sets were identified with bioDBnet.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA sequencing data reported in this paper is
GEO: GSE99133. The project identifier for the mass spectrometric data
reported in this paper is PRIDE (ProteomeXchange Consortium via the PRIDE
repository): PXD006575.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.01.033.
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